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Abstract: The main concern of long-term use of trastuzumab remains its association
with potential cardiac side effects. Although these side effects are real, they are probably
overemphasized. We report the case of a woman with metastatic breast cancer, who is currently in
complete remission, and who received trastuzumab continuously for more than 9 years, without
any significant cardiac toxicity.
Keywords: metastatic breast cancer, long survival, trastuzumab

Introduction
Trastuzumab (Herceptin®) is a humanized monoclonal antibody inhibitor of the human
epidermal growth factor receptor 2 (Her2/neu). Her2/neu, a transmembrane tyrosine
kinase receptor belonging to the epidermal growth factor receptor family is overexpressed in approximately 20% of invasive breast cancers. Activation of Her2 has been
shown to result in tumor growth and progression.
Since its approval in the USA in 1998, trastuzumab has revolutionized the management of localized Her2/neu-positive breast cancer, especially in those who express the
Her2/neu protein. According to observational data, the use of trastuzumab in women
with early breast cancer has reversed the worst prognosis associated with Her2-positive
status. In a multivariate analysis published in 2010, trastuzumab recipients with
Her2/neu-positive disease had a 44% reduction in the risk of death, versus women
with Her2-negative disease (hazard ratio [HR]: 0.56, 95% confidence interval [CI]:
0.45–0.69; P,0.0001).1
Additionally, trastuzumab has been shown to improve both the progression-free
survival (PFS) and the overall survival (OS) rate of patients with metastatic breast
cancer. In a pivotal Phase III trial, trastuzumab, in combination with chemotherapy, was
administered as first-line therapy to Her2-positive metastatic breast cancer patients. The
time to disease progression was significantly prolonged (7.4 months versus 4.6 months).
Also, the OS rates (25 months versus 20 months) improved, when compared against
chemotherapy alone.2
It is not clear if continuing trastuzumab after progression improves the OS of women
with metastatic breast cancer. Accordingly, the final overall analysis of the GBG-26/
BIG 3-05 Phase III study did not demonstrate a significant survival benefit for treatment beyond progression with trastuzumab. In the same study, a non-planned, post hoc
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analysis suggested that patients receiving anti-Her2 treatment
as third-line therapy may benefit from trastuzumab, as they
had better postprogression survival than those not receiving
the treatment (18.8 months versus 13.3 months; HR:0.63;
P=0.02).3
Trastuzumab is an effective targeted agent. However, it
is estimated that, for each life saved, 10–25 patients develop
heart disease. For example, the N9831 (Arm C) and NSABP
B31 joint analysis revealed that, on average, for every three
lives saved by reducing breast cancer, two patients died of
heart disease or other complications.4 Slamon et al reported
a 27% incidence of cardiac events in patients treated with the
combination anthracyclines-trastuzumab, compared against
12% with the combination paclitaxel-trastuzumab.2
Despite the introduction of trastuzumab, Her2/neu-positive
metastatic breast cancer remains an aggressive disease, and
the majority of patients progress within 1 year of starting
the treatment.
Here, we present the case of a postmenopausal woman
with metastatic breast cancer, currently in complete remission, who received trastuzumab for more than 9 years, without
any significant cardiac toxicity.

Case report
In July 2005, a 53-year-old woman presented to a medical oncologist with a complaint of a left breast mass, of
several years duration. The patient was in very good health
otherwise, without any comorbidities, and she was taking
no medications. On physical examination, peau d’orange
was noted in her left breast (Figure 1) and a subcentimetric
mass was palpable above her left nipple. Several enlarged
lymph nodes were also palpable in her left axilla. The tumor
was biopsied and the biopsy results revealed tubular breast

Figure 1 Image of the inflammatory breast lesion in June 2005.
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carcinoma (Figure 2). The tumor was found to be estrogen
receptor-(ER) positive (40%–50%) (Figure 3), progesterone
receptor-(PR) positive (10%–15%) (Figure 4), and Her2/neu
positive (2+) (Figure 5). Her2/neu positivity was confirmed
by fluorescence in situ hybridization. The patient had a computed tomography (CT) of the chest/abdomen/pelvis, which
revealed bilateral lung and spinal bone metastasis. At that
time, she was staged clinically as T4cN2M1.
The patient was treated for more than 1 year with
docetaxel (70 mg/m2) every 3 weeks, in combination with
weekly trastuzumab (2 mg/kg), with good clinical response.
The erythema of the skin improved and the breast tumor
was no longer palpable. In September 2006, she had a
modified radical mastectomy with axillary dissection. The
mastectomy specimen was found to be cancer-free, and all
ten lymph nodes removed from the axilla were negative
(pathological stage: T0N0Mx). Postoperatively, the patient
continued to receive docetaxel (70 mg/m2) and trastuzumab
for more than 2 years, until December 7, 2008. Of note,
on an echocardiogram done in February 2008, the ejection
fraction was slightly decreased (48%). Given the fact she did
not have any cardiac symptoms, the decision was made to
continue the weekly trastuzumab treatment. On a follow-up
echocardiogram done 3 months later, the ejection fraction
had normalized (53%).
In December 2008, the patient was found to have
evolving pulmonary metastasis, in addition to new bone
metastasis. At that time, the patient was given four cycles
of docetaxel (70 mg/m2) and epirubicin (90 mg/m2), with
minimal response, followed by four cycles of gemcitabine
(1,250 mg/m2) and cisplatin (75 mg/m2), which were subsequently followed by two more cycles of gemcitabine

Figure 2 Breast biopsy – sheets of malignant ductal cells in an invasive ductal
carcinoma moderately differentiated (G2), H&E stain, 100×.
Abbreviation: H&E, hematoxylin and eosin.
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Figure 3 Breast biopsy – positive nuclear immunostaining for estrogen receptors
(semiquantitative evaluation is 40%–50%), LSAB technique, 200×.
Abbreviation: LSAB, labeled streptavidin biotin.

Figure 5 Breast biopsy – positive incomplete membrane immunostaining for
c-erbB2 protein (score 2+), LSAB technique, 100×.
Abbreviation: LSAB, labeled streptavidin biotin.

(1,250 mg/m2) and carboplatin (area under the curve = 5)
(cisplatin was changed to carboplatin because of renal toxicity), with excellent response.
In June 2009, CT scan of the chest revealed a normal
study, and her bone scan did not show any evidence of active
bone disease. At that point, the patient had received a total of
141 weekly cycles of trastuzumab. In July 2009, the patient was
started on letrozole (2.5 mg orally per day) and trastuzumab
(2 mg/kg) every 2 weeks and, until July 2014, received an additional 92 cycles of biweekly trastuzumab. A CT of the chest and
an echocardiogram, performed in June 2014, were normal.
The foregoing indicates that, in this patient, the continuous trastuzumab treatment was generally well tolerated. The
only notable complication was a paronychial infection, which
resolved entirely with antibiotic treatment.

To summarize, over the duration of more than 9 years,
from June 2005 to July 2014, the patient received 233 doses
of 150 mg trastuzumab, without significant cardiac toxicity.
The most recent echocardiogram, performed in June 2014,
was normal (ejection fraction: 60%).

Figure 4 Breast biopsy – positive nuclear immunostaining for progesterone
receptors (semiquantitative evaluation is 10%–15%), LSAB technique, 100×.
Abbreviation: LSAB, labeled streptavidin biotin.
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Discussion
We report the case of a patient who was diagnosed with bone
and bilateral lung metastatic breast cancer, and who was still
alive and disease-free after 9 years of continuous treatment
with trastuzumab, in combination with chemotherapy or
hormonal treatment.
There are several factors that may have contributed to
the exceptionally long survival of this patient.
First, several retrospective studies indicate that, in the
setting of metastatic disease, women who undergo surgical
resection of the primary tumor have longer survival than those
whose primary tumor is left intact.5–7 After receiving 1 year of
neoadjuvant chemotherapy, this patient also had local treatment of her primary tumor, but both the mastectomy tissue
and the resected lymph nodes were cancer-free.
Also, postsurgery, this patient received various chemotherapy regimens in combination with trastuzumab for more
than 30 months. Subsequently, after achieving complete
remission, trastuzumab was continued in combination with
hormonal treatment. Hence, it is difficult to determine which
of the agents used – chemotherapy, hormonal therapy, or trastuzumab – had the highest contribution to her long survival.
In September 1998, the US Food and Drug Administration
approved trastuzumab as a first-line therapy for Her2-positive
metastatic breast cancer. The approval was based on the
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observation that, in women with advanced Her2-positive
breast cancer, the up front use of trastuzumab, in combination
with chemotherapy, prolongs life.
In the English literature, there are several published case
reports of prolonged survival rates associated with longterm trastuzumab use.8–12 However, in none of these cases
was trastuzumab administered for such a long time as in our
patient (longer than 9 years) (Table 1). All five of the patients
described in the case reports presented initially with localized disease, and had surgery. The patient described here had
metastatic disease on presentation and had surgery more than
1 year from diagnosis, after demonstrating an exceptionally
favorable response to chemotherapy and trastuzumab. In two
of the five previously published case reports, trastuzumab
was administered as a single agent,10,11 and in one case it was
given in combination with chemotherapy.12
In two cases, it was initially used in combination with
chemotherapy and then alone in maintenance.8,9 Interestingly, the tumors of all these five patients were hormone
receptor-negative, as opposed to the tumor of our patient,
which was hormone receptor-positive. Also, our patient was

older (53 years) than the patients described in the previously
published case reports (Table 1).
In 2012, a series of 217 patients with Her2/neu-positive
breast cancer was reported at the Thirty-Fifth Annual
CTRC-AACR San Antonio Breast Cancer Symposium.13
Fifty-six (26%) of these patients survived longer than 5 years.
The median disease-free interval was 17 months. In 39 cases
(70%), the tumors were hormone receptor-positive. Of note,
all the complete responses were observed after one line of
taxane-based chemotherapy, given in combination with
trastuzumab. Seven patients who had a complete response
continued trastuzumab, and all hormone receptor-positive
patients received hormonotherapy as well.
An analysis of the characteristics of the demographics,
disease characteristics, and treatment history of patients
with metastatic breast cancer treated with trastuzumab was
also presented in 2012 in San Francisco at the ASCO Breast
Cancer Symposium.14 RegistHER was a multicenter, prospective, observational, US-based cohort study of 1,023 patients
with Her2/neu-positive metastatic breast cancer diagnosed
within 6 months of enrollment. The objectives of the

Table 1 Previously published case reports
Year of publication
and reference number

Age at diagnosis
Stage at diagnosis
Histology status
Receptor status
Surgery performed

Location of metastasis
Duration of trastuzumab use

Treatment administered

200511

43
Stage IIB
Invasive ductal
ER-PR-Her2/neu 3+
Mastectomy
36
Stage IIB
Invasive ductal
ER-PR-Her2/neu 3+
Mastectomy
46
Stage IIIA
Invasive ductal
ER-PR-Her2/neu 3+
Lumpectomy
34
Stage IIIA
Invasive ductal
ER-PR-Her2/neu 3+
Mastectomy
29
Stage IIIB
Invasive ductal
ER-PR-Her2/neu overexpressed
Mastectomy

Liver
3 years and 9 months

Trastuzumab alone weekly

Liver
5 months

Trastuzumab alone, every 3 weeks

Liver
2 years and 2 months

Trastuzumab every 3 weeks,
with paclitaxel weekly for 4 months,
then trastuzumab alone

Liver
7 years

Trastuzumab weekly, with 5FULV-MTX for 4 months,
then with vinorelbine
and gemcitabine for 9 months,
then trastuzumab alone, weekly
Trastuzumab every 4 weeks,
with capecitabine for 2 weeks on/
1 week off

200610

20079

20108

201212

Pulmonary and bone metastases
5 years

Abbreviations: Her2/neu, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor; 5 FU, 5 fluorouracil; LV, leucovorin; MTX, methotrexate.
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registHER study were to describe the natural disease history
and treatment patterns for patients with Her2/neu-positive
metastatic breast cancer, and to investigate the associations
between different treatments and outcomes. There were
404 patients in the registry found to have long-term survival (LTS). LTS was defined as survival $36 months from
metastatic diagnosis. Of the LTS patients, 356 were treated
with front-line therapy, and 106 of them (29.8%), received
chemotherapy and hormonal treatment, in addition to trastuzumab. Prognostic factors associated with OS in all treated
patients were assessed using multivariate Cox regression
analysis. Factors associated with reduced risk of mortality
included: ER-positive or PR-positive disease; metastasis to
bone only, or bone plus breast or node/local sites; first-line
trastuzumab use; and first-line taxane use.
The authors of the registHER study also recently published an updated report.15 In this report, they found that,
compared against patients who received first-line trastuzumab
and chemotherapy only, patients who received first-line
trastuzumab and chemotherapy in addition to hormonal
therapy had longer median PFS times (20.4 months versus
9.5 months; adjusted HR: 0.53, 95% CI: 0.42–0.68); a statistically significant reduction in the risk of death was observed
(adjusted HR: 0.50, 95% CI: 0.36–0.70). Also, sequential use
of chemotherapy and hormonal therapy was associated with
improved OS times, when compared against concurrent use
(adjusted PFS HR: 0.81, 95% CI: 0.54–1.21; adjusted OS
HR: 0.48, 95% CI: 0.26–0.89).
The patient described here was treated with both frontline taxanes and trastuzumab, and had a hormone receptorpositive breast cancer. Based on the registHER study findings,
this may have contributed to the good initial response and
to the subsequent relatively indolent course of her disease.
On the other hand, given the presence of bilateral lung and
bone metastasis, our patient fits only partially the favorable
prognostic criteria described in the registHER study.
Clinical evidence supports continued trastuzumab treatment after initial progression. For example, a prospective,
randomized, German study,3 in which 112 patients with
Her2-positive metastatic breast cancer, initially progressed
on a trastuzumab-based therapy (GBG-26/BIG 3-05 study),
showed that the patients enrolled in the trastuzumabcapecitabine arm had a a longer PFS (8.2 months versus
5.6 months) and OS (25.5 months versus 20.4 month),
compared against patients enrolled in the capecitabine only
arm, but the improvement in OS was not statistically significant (P=0.257).3 Trastuzumab was also continued in our
patient, after initial progression, in combination with two
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d ifferent chemotherapy regimens. Hence, this may explain
this patient’s long PFS.
Notwithstanding the above, the main concern of longterm use of trastuzumab remains the potential cardiac side
effects. A very thorough definition of cardiotoxicity was
formulated by the cardiac review and evaluation committee
(CREC) supervising the trastuzumab clinical trials.16 CREC
established the following criteria to confirm or revise a preliminary diagnosis of cardiac disease: 1) cardiomyopathy
characterized by a decrease in cardiac left ventricular ejection fraction (LVEF) that was either global or more severe in
the septum; 2) symptoms of congestive heart failure (CHF);
3) associated signs of CHF, including, but not limited to, S3
gallop, tachycardia, or both; and 4) decline in LVEF of at least
5%, to less than 55%, with accompanying signs or symptoms
of CHF, or a decline in LVEF of at least 10%, to below 55%,
without accompanying signs or symptoms.16
The degree of cardiotoxicity induced by trastuzumab
varies, and it ranges from asymptomatic left ventricular
dysfunction, diagnosed during the routine follow-up by a
decrease in the ejection fraction, to severe symptomatic CHF,
although the latter is a rare event, occurring in less than 3%
of patients treated with trastuzumab.17 As opposed to Type I
chemotherapy-related cardiac dysfunction (CRCD), caused
by classical chemotherapy agents such as anthracyclines,
alkylating drugs, and microtubule inhibitors, trastuzumab has
been associated with Type II CRCD, which is a completely
different entity.18 The characteristics of Type II CRCD are:
it is not dose-related; it occurs only in a fraction of patients;
it appears to be highly reversible, in contrast with Type I
CRCD;16 it has a high likelihood of recovery, even when
the drug is continued;19 its severity widely varies; and it is
not associated with identifiable ultrastructural abnormalities (reviewed in Ewer and Lippman).18 In a meta-analysis
published in 2008 that included 9,117 patients, there were
more cardiac toxicities of Grade 3 or 4 after trastuzumab
use (203/4,555; 4.5%) compared against no trastuzumab
(86/4,562), and the likelihood of cardiotoxicity was 2.45fold higher in trastuzumab-treated patients.20 Also, in the
registHER study, in the cohort of LTS patients, the incidence
of any cardiac safety event (Grade $3) was 8.9%, and this
was only slightly higher than in all treated patients (7.8%).
Left ventricular dysfunction was the most prevalent cardiac adverse event in LTS (5.0%), as well as in all treated
patients (2.6%).15
In clinical practice, the decrease in LVEF is usually
asymptomatic, and the trastuzumab package insert recommends baseline LVEF evaluation and reassessment every
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3 months during and upon completion of the treatment.21
In our patient, given the lack of symptoms and the excellent tolerance of the drug for a prolonged period of time,
echocardiograms were done every 4 months.
The treatment of trastuzumab-associated cardiotoxicity
with beta blockers (BB), angiotensin-converting enzyme
inhibitors (ACE-I) or angiotensin receptor blockers (ARB),
or a combination of these agents, remains empirical, and
further randomized clinical trials are needed in order to
demonstrate their efficacy.
Trastuzumab-associated cardiotoxicity treatment should
be implemented in accordance with the various published
guidelines. For instance, the American Association of Heart
Failure Guidelines indicate that asymptomatic decreased
LVEF below 40% is an indication for therapy with BB,
ACE-I, or ARB.22 Also, ESMO Guidelines recommend to
consider treatment with BB or ACE-I if the ejection fraction
is less than 50%, and to start treatment if the LVEF is less
than 40%.23 With careful monitoring, cardiac side effects can
be identified early and, based on the published data, in the
majority of cases (79%), LVEF will improve with medical
treatment.16 In patients with good clinical response to trastuzumab, in which we anticipate a prolonged administration of
the drug, even though the patient remains asymptomatic, it
might be reasonable to start treatment with a BB, an ACE-I,
or a combination of both, if the LVEF declines below 40%.
The trastuzumab package insert recommends withholding
trastuzumab for at least 4 weeks in either of the following
situations: $16% absolute decrease in LVEF from pretreatment values, or LVEF below institutional limits of normal
with $10% absolute decrease in LVEF from pretreatment
values.21 Trastuzumab may be resumed if, within 4–8 weeks,
the LVEF returns to normal limits and the absolute decrease
from baseline is #15%.21 These recommendations are easy
to follow and they should also guide the treatment of patients
receiving trastuzumab for prolonged periods of time.
At present, there are several ongoing trials addressing the
question of pharmacological prophylaxis of cardiotoxicity
associated with trastuzumab, using BB or ACE-I.24,25
It is important to determine in advance which patients
are at risk for trastuzumab-related cardiac side effects. In
clinical trials, there are several risk factors associated with
trastuzumab-induced cardiotoxicity identified so far: prior
treatment with anthracycline treatment; a borderline LVEF;
prior treatment with antihypertensive medication; older age;
and a body mass index .25 kg/m2.26 The patient described
here had none of these risk factors, and this may have been
also one of the reasons she tolerated trastuzumab so well.
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The majority of patients treated with trastuzumab do not
develop any side effects related to this drug. As mentioned
before, trastuzumab-associated cardiac toxicity is not doserelated and, at present, there are no markers that can either
predict which patients will develop cardiac toxicity or, when
asymptomatic decrease in LVEF is diagnosed, in which
patients LVEF will normalize without resort to treatment.

Conclusion
Chemotherapy and hormonal treatment play a key role in the
treatment of metastatic breast cancer. The debate regarding
the continuation of trastuzumab in the metastatic setting
after initial progression is not settled yet, and our case suggests that, for some patients, this strategy may be beneficial.
Trastuzumab may act synergistically in combination with
chemotherapy and hormonal treatment, and could be used
as the foundation to which different therapeutic agents are
added.
In the metastatic setting, the benefit of using trastuzumab
in front-line in patients with Her2/neu-positive disease is
clearly proven, but the advantage of continuing trastuzumab
after progression on trastuzumab is not as firmly established.3
In the absence of a randomized, prospective study addressing directly the different factors associated with LTS, a case
to case risk-benefit analysis, taking into consideration the
prognostic of the individual patient versus the risk of cardiotoxicity associated with the long-term use of trastuzumab,
should be performed. Of note, the 1-year mortality of patients
with severe heart failure is less than that for patients with
metastatic breast cancer.19
In some Her2/neu-positive metastatic breast cancer
patients, like our patient, the long-term use of trastuzumab,
with careful cardiac monitoring, in combination with chemotherapy and hormonal therapy, may help achieve prolonged
survival and maybe even a cure.
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